Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis

The role of inhaled corticosteroids for outpatient COVID-19 is evolving. Meta-analysis of reported clinical trials estimated probability of any effect for symptom resolution by day 14 at 100% and hospitalisation at 89.3%, respectively. https://bit.ly/3B2sDUi

Detalles Bibliográficos
Autores principales: Lee, Todd C., Bortolussi-Courval, Émilie, Belga, Sara, Daneman, Nick, Chan, Adrienne K., Hanula, Ryan, Ezer, Nicole, McDonald, Emily G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068973/
https://www.ncbi.nlm.nih.gov/pubmed/35144994
http://dx.doi.org/10.1183/13993003.02921-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068973/
https://www.ncbi.nlm.nih.gov/pubmed/35144994
http://dx.doi.org/10.1183/13993003.02921-2021

Ejemplares similares